An Australian delegate comprised of bio-officials spanning research, academia, and industry, recently visited Korea to discuss partnerships with domestic biotech companies.At a meeting between the delegates and Korean biotech companies on Tuesday evening, Korea Biomedical Review sat down with two of
Middle-aged women with high diastolic blood pressure are 1.7 times likelier to develop breast cancer, so they need to be more careful with their usual BP control, a study said Wednesday.Hypertension and breast cancer are two of the most prevalent chronic diseases globally. Moreover, according to the
Celltrion said Monday it proved the effectiveness and safety of RemsimaSC (pipeline name: CT-P13 SC), an autoimmune disease treatment, in two global phase 3 trials. RemsimaSC is a subcutaneous injection (SC) form of infliximab, widely used in TNF-α inhibitor market. It is the world’s first inflixima
A team of researchers at Seoul National University Hospital together with the National Cancer Control Institute published a study that revealed brain damage from long-term air pollution exposure.Ambient air pollution is one of the most important global health issues and Korea is frequently affected
Lilly Korea said on Monday that its CDK 4&6 inhibitor Verzenio (ingredient: abemaciclib) has been approved by the Ministry of Food and Drug Safety (MFDS) on Friday for an additional indication for high-risk early breast cancer.Specifically, it was approved for hospital patients with a high risk of r
Celltrion has won new “domestic” approval for a Humira (adalimumab) biosimilar with the same dosage and formulation as the currently marketed product, drawing the industry’s attention to the reason.According to the Ministry of Food and Drug Safety, Celltrion obtained domestic approval for Yuflyma Pe
Macrogen, a Korean genome analysis company, held a groundbreaking ceremony on Tuesday to commence construction of the “nation's largest” genome foundry, Macrogen Sejong Campus, in Sejong City for innovation in genome analysis.Macrogen Chairman Seo Jung-sun and Global Business CEO Lee Su-kang were am
Researchers at the Catholic University of Korea said they discovered a novel cytokine immune protein, p40, and EB13, that can control immune T cells for the treatment of intractable autoimmune diseases like rheumatoid arthritis.The interleukin (IL)-12 cytokine family is associated with T cells that
AptaBio, a developer of innovative drugs for intractable diseases, said on Tuesday that it will present the treatment effect of APX-NEW, an oxidative stress drug for the treatment of Parkinson's disease, at the Society for Neuroscience (SFN) on Nov.12-16 in San Diego, the U.S.APX-NEW is a drug with
Korea Research Institute of Bioscience & Biotechnology (KRIBB) said on Monday that its researchers have discovered proteins to alleviate human inflammation to aid in the diagnosis of inflammatory diseases and the development of therapeutic technologies.Inflammation is a complex immune response that
Genome & Company, specializing in microbiome therapeutics, said on Friday that it published study results showing Bifidobacterium longum and Bifidobacterium bifidum bacteria located in the gut were associated with protecting against diet-induced obesity.The research team analyzed intestinal microorg
Day two of DTx Asia began with experts in the APAC region discussing different ways to integrate digital therapeutics (DTx) into healthcare and its respective opportunity costs, at the Novotel Ambassador Hotel in Seoul on Wednesday.The panelists included EverEx Founder & CEO Chan Yoon who served as
DTx Asia, a conference inviting healthcare companies specializing in digital therapeutics (DTx) to engage in dialogues surrounding the establishment of the industry in Asia, launched at the Novotel Ambassador Hotel in Gangnam, Seoul on Tuesday.The DTx conference also has a series in America East and
Spouses of Ambassadors in Korea had a chance to learn why Korea’s cancer mortality rate was lowest despite the lowest health cost among 21 high-income countries.The Hanaro Medical Foundation (HMF), a health checkup institution, welcomed 14 members from the Ambassadors' Spouses Association in Seoul (
Gangnam Severance Hospital (GSH) researchers demonstrated that antibody drug conjugate (ADC), REGN5093-M114, can overcome mesenchymal-epithelial transition (MET) gene-based EGFR target mutant non-small cell lung cancer (NSCLC).Lung cancer is classified into NSCLC and small cell lung cancer (SCLC) ac
HLB said on Friday that the anticancer vaccine candidate ITI-3000 aiming to treat Merkel cell cancer (MCC) via its U.S. subsidiary Immunomic Therapeutics has received fast track designation by the FDA.ITI-3000 is an anticancer vaccine made by combining lysosomal-associated membrane protein 1 (LAMP1)
Although biopharmaceutical firms commit considerable resources annually to treat neurological diseases, many still remain without a cure. This is precisely the gap that Canadian biotech, Ananda, is looking to fill by accelerating the development of therapies for neurological diseases. On a related n
Celltrion, which is developing CT-P47, the biosimilar of Actemra (tocilizumab), has set about to diversify its formulation.According to informed sources, Celltrion received approval from the Ministry of Food and Drug Safety for the domestic phase 1 clinical trial of CT-P47, which treats rheumatoid a
SK Bioscience said on Thursday that it has conducted a vaccine production training for people from developing countries at the L House, a vaccine plant located in Andong, North Gyeongsang Province, following the World Health Organization’s (WHO) designation of Korea as a global biomanufacturing trai
Orum Therapeutics, specializing in tumor-directed targeted protein degraders (TPDs), said on Tuesday that it completed the first patient dose with ORM-5029 in a U.S. phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.ORM-5029 is one of two lead programs from the company’s